A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
GlaxoSmithKline's CV0501 mRNA COVID-19 vaccine is positioned as a booster option for individuals previously vaccinated with Comirnaty or Moderna vaccines. Given the ongoing need for booster vaccinations due to waning immunity and emerging variants, this asset could capture a significant share of the booster market. The competitive landscape includes established players like Pfizer-BioNTech and Moderna, as well as emerging mRNA candidates. Successful safety and immunogenicity results could enhance GSK's portfolio and strengthen its position in the rapidly evolving vaccine market.
Indication: COVID-19
Modality: vaccine
Target: mRNA-based vaccine targeting SARS-CoV-2 spike protein.
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: mRNA-based vaccine targeting SARS-CoV-2 spike protein.
View original source fields
Condition raw: COVID-19, SARS-CoV-2
Condition normalized: COVID-19, SARS-CoV-2
Modality raw: vaccine
Modality normalized: vaccine
Target raw: mRNA-based vaccine targeting SARS-CoV-2 spike protein.
Target normalized: mRNA-based vaccine targeting SARS-CoV-2 spike protein.